Qube Research & Technologies (QRT)
BTAI icon

Qube Research & Technologies (QRT)’s BioXcel Therapeutics BTAI Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,384
Closed -$65.3K – 4481
2023
Q4 		$65.3K Buy
1,384
+924
+201% +$51.4K ﹤0.01% 3238
2023
Q3 		$18.6K Buy
+460
New +$46.5K ﹤0.01% 3167
2021
Q4 		– Sell
-778
Closed -$378K – 2550
2021
Q3 		$378K Buy
778
+78
+11% +$34.3K ﹤0.01% 1372
2021
Q2 		$325K Sell
700
-35
-5% -$19.1K ﹤0.01% 1525
2021
Q1 		$508K Sell
735
-1,160
-61% -$933K 0.01% 1167
2020
Q4 		$1.4M Buy
+1,895
New +$1.48M 0.02% 759

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Qube Research & Technologies (QRT)'s BTAI Position: Q1 2024 in Review

Qube Research & Technologies (QRT) sold out of BioXcel Therapeutics (BTAI) in Q1 2024, closing a stake of 1,384 shares — an estimated $65.3K sold.

Qube Research & Technologies (QRT) first reported a position in BTAI in Q4 2020 and held it in 6 quarters. The position peaked at $1.4M in Q4 2020. 73 funds tracked by Wall St. Rank hold BTAI as of Q1 2024.

  • Qube Research & Technologies (QRT) reported no remaining BioXcel Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 1,384 BioXcel Therapeutics shares in Q1 2024, an estimated $65.3K.
  • Qube Research & Technologies (QRT) first reported a position in BioXcel Therapeutics in Q4 2020 and held it in 6 quarters.
  • Qube Research & Technologies (QRT)'s BioXcel Therapeutics position peaked at $1.4M in Q4 2020.
  • 73 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2024.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2024, filed 14 May 2024.